The Food and Drug Administration on Tuesday approved pimicotinib (Pimjetmi, EMD Serono), a once-daily oral kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor when surgery may worsen function or cause severe morbidity, the agency said.

Efficacy was evaluated in MANEUVER, a Phase 3, double-blind, international trial that randomized patients 2:1 to pimicotinib 50 mg once daily or placebo, the FDA said. The ASCO Post (opens in new tab) reported that the objective response rate at week 25, assessed by a blinded independent review committee using RECIST v1.1, was 56% with pimicotinib versus 3% with placebo.

The prescribing information includes warnings for liver toxicity, embryo-fetal toxicity, and increased serum creatinine without affecting renal function, the FDA said. The most common side effects, occurring in more than 20% of patients, were itching, rash, swelling of the face and around the eyes, fatigue, nausea, headache and peripheral edema.

The recommended dose is 50 mg once daily with or without food. The review was conducted under Project Orbis with regulators in Australia, Canada, Israel, Switzerland and the United Kingdom, and the drug received fast-track and breakthrough designations, the FDA said.